All News

Article

Disease Modification, Disparities and the Next Therapeutic Frontier in Gout

Audrey Gibson, MsPAS, PA-C

Gout management has entered what Dr. Robert Terkeltaub MD from UC San Diego described as its “disease-modifying era,” during his talk at RheumNow Live 2026. In a recent comprehensive review of the past, present, and future of gout therapy, the central message was clear: “We can really apply disease modification to gout based on prospective, randomized controlled trials.”

Dr. John Cush Tweet
RheumNow
RT @gibson_rheumPAC Helicobacter pylori Update: H. Pylori remains the most common chronic bacterial infection worldwide, acquired in childhood and lifelong if untreated. Its clinical impact spans far beyond dyspepsia—from ulcers to malignancy. #RNL26 tis
Dr. John Cush Tweet
RheumNow
“The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy.” - Martin Luther King, Jr.
Dr. John Cush Tweet
RheumNow
RT @gibson_RheumPAC Axial PsA remains an area of active investigation. IL-17 inhibitors show consistent benefit, while IL-23 data are emerging—highlighting nuances when axial symptoms drive treatment choice. #RNL26 https://t.co/XFL3Sf8iK4
Dr. John Cush Tweet
RheumNow
RT @Gibson_RheumPAC A good reminder: PsA treatment should be domain-based. Skin, peripheral joints, axial disease, and enthesitis may each favor different pathways. #RNL26 https://t.co/IUCsdlNopo
Dr. John Cush Tweet
RheumNow
RT @Gibson_RheumPAC Important rheumatology signal: dupilumab-associated inflammatory arthritis. Usually seronegative, imaging-supported, and sometimes persistent despite normal labs. Co-management and careful work-up are essential.#RNL26 https://t.co/r73cSZC59s
Dr. John Cush Tweet
RheumNow
Most inhibition of inflammation is via the brain. More GLP1 and GIP1 receptors are in the brain, more than the gut. @RWCSmtg #RWCS26 https://t.co/CNzUqteBLg
Dr. John Cush Tweet
RheumNow
#RNL26 Haque @HopkinsRheum 1/2 of Americans will be obese by 2030 "Obesity is common & obesity is expensive" Adipose tissue - active endocrine organ -> cytokines, chemokines, adipokines Leads to inflamm axis - risk factor similar to 🚬, higher activity, worse response https://t.co/yQLTpE7reY
Dr. John Cush Tweet
RheumNow
RT @ericdeinMD #RNL26 Dx Modification of OA @Tuhina_Neogi Challenge in drug develop: Models in young animal, not like human OA Trial enrollment in pts w late, establ OA- not early interv tx Many paths to OA - target mechanism to correct pt Slow progress of dx, $$ Endpt? Sx or
Dr. John Cush Tweet
RheumNow
RT @Gibson_RheumPAC GLP-1 receptor agonists do more than promote weight loss. They impact insulin resistance, inflammation, cardiovascular risk—and may influence musculoskeletal disease. #RNL26 https://t.co/ypKnOJojAm
Dr. John Cush Tweet
RheumNow
RT @Gibson_RheumPAC Obesity doesn’t just increase risk of rheumatic diseases-it worsens outcomes. Patients with obesity have higher disease activity, poorer biologic response, and 20–25% lower remission rates in inflammatory arthritis. #RNL26
Dr. John Cush Tweet
RheumNow
RT @Gibson_RheumPAC Nearly 50% of U.S. adults may meet criteria for obesity by 2030. For rheumatologists, it directly impacts disease activity, outcomes, and treatment response. #RNL26 https://t.co/cpy4LBBPHc
Dr. John Cush Tweet
RheumNow
RT @gibson_RheumPAC Osteoarthritis affects 600 million people worldwide—yet we still have no approved disease-modifying therapies. A powerful opening to this talk on why OA drug development keeps missing the mark. https://t.co/wBUN3lux6X
×